# Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging

> **NCT04120766** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Gregory Jicha, MD, PhD** · enrollment: 64 (actual)

## Conditions studied

- Dementia
- Mild Cognitive Impairment

## Interventions

- **DRUG:** Nicorandil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04120766
- **Lead sponsor:** Gregory Jicha, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-01
- **Primary completion:** 2026-09-01
- **Final completion:** 2026-11-30
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2025-12-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04120766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04120766, "Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT04120766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*